Skip to main content
Premium Trial:

Request an Annual Quote

New Zealand Patent Office Issues Notice of Allowance for MDRNA Application

Premium

MDRNA said this week that it has received a notice of allowance from the Intellectual Property Office of New Zealand on a patent application covering siRNAs and delivery systems with therapeutic potential.

The application, No. 553828, is entitled, "Methods of Treating an Inflammatory Disease by Double-Stranded Ribonucleic Acid," according to the company.

"Allowed claims cover small interfering RNAs directed against the tumor necrosis factor gene, as well as several of the company's key nucleic acid condensing and delivery peptide motifs in combination with a siRNA directed against TNF," MDRNA added.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.